Version history

{
  "session_id": "sess_SDA-2026-04-08-gap-pubmed-20260406-062229-35a642ca",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "us.anthropic.claude-sonnet-4-20250514-v1:0",
  "action": "support",
  "content": "**Existing Clinical Landscape:**\n- **DDR Inhibitors in Cancer:** Extensive pipeline (PARP inhibitors: olaparib, talazoparib; ATR inhibitors: AZD6738)\n- **Neurodegeneration DDR:** No current clinical programs targeting DDR in neurodegeneration\n- **PPI Inhibitors:** Limited success (BCL-2 inhibitors, MDM2 inhibitors represent rare successes)\n\n**Competitive Assessment:**\n- **Blue Ocean:** No direct competition in neurodegeneration DDR space\n- **Cancer Spillover Risk:** Cancer DDR programs could pivot to neurodegeneration\n- **Technical Barriers:** PPI druggability remains challenging despite advances\n\n**Safety Concerns:**\n- **Essential Function Disruption:** RAD50-TBP interaction may be crucial for normal DNA repair\n- **Cancer Risk:** Impaired DDR could increase malignancy risk in long-term treatment\n- **Immune Dysfunction:** DDR proteins involved in immune surveillance\n\n**Development Timeline & Cost:**\n- **Target Validation:** 12-18 months ($3-8M) - Confirm PPI and functional relevance\n- **Hit Identification:** 18-36 months ($10-25M) - HTS, fragment-based drug discovery\n- **Lead Optimization:** 24-36 months ($15-40M) - ADME, selectivity optimization\n- **IND-Enabling:** 18-24 months ($20-35M) - Extensive safety studies for novel target\n- **Phase 1:** 18-24 months ($25-50M) - Extended safety evaluation\n- **Total to Phase 1:** 7-10 years, $73-158M\n\n**Key Risks:**\n1. **Druggability:** RAD50-TBP interface may lack deep binding pockets\n2. **Selectivity:** Distinguishing pathological vs. physiological interactions\n3. **Regulatory:** Novel mechanism requires extensive non-clinical validation\n\n## Overall Recommendation\n\n**Most Viable Approach: Modified ASO Strategy**\n- Focus on well-characterized dilncRNAs from specific damage contexts\n- Partner with established ASO companies (Ionis, Antisense Therapeutics)\n- Leverage existing CNS delivery infrastructure\n- Estimated development cost: $90-175M to Phase 2\n\n**Least Viable: MRN-PIC Inhibitors**\n- High technical risk for PPI targeting\n- Uncertain therapeutic window\n- Extensive safety requirements for novel DDR target\n- Estimated cost: $73-158M just to reach Phase 1\n\n**Critical Next Steps:**\n1. Sequence and characterize dilncRNAs from human neurodegeneration samples\n2. Validate nuclear delivery of ASOs to damage foci\n3. Establish disease-relevant biomarkers for target engagement\n\nThe ASO approach offers the best risk-adjusted return, leveraging established technology platforms while addressing a novel biological target.",
  "tokens_used": "624",
  "persona_id": "persona-domain_expert"
}